SymBio Pharmaceuticals Limited

4582.T
Drug Manufacturers - Specialty & Generic
2026/11/03 19:58 Updated
Market Cap: $21.8M (¥3.4B)
Stock Price: $0.27 (¥43)
Exchange Rate: 1 USD = ¥157.98

Notice of Monthly Exercise Status for the 70th and 71st Stock Acquisition Rights Issued by Third-Party Allotment

Discloses the monthly exercise status of stock acquisition rights (70th and 71st). The number of shares to be delivered for the subject month was 2,830,000 shares; exercised rights numbered 28,300 cases, with exercised shares totaling approximately 5,600 shares equivalent. Unexercised rights at month-end amounted to 408,700 shares, compared with 437,000 shares at the end of the prior month. Exercise restrictions were complied with; the exercise ratio was 3.5%.

Importance:
Page Updated: November 2, 2026
IR Disclosure Date: November 2, 2026

Key Figures

  • Number of shares to be delivered in the subject month: 2,830,000 shares
  • Number of stock acquisition rights exercised during the subject month: 28,300 cases
  • Total number of issued stock acquisition rights: 480,000 cases

AI要約

Overview of Monthly Exercise Status

This report discloses the monthly exercise status for October 2026 of the 70th and 71st stock acquisition rights issued by third-party allotment. The number of shares to be delivered in the subject month was 2,830,000 shares; the number of stock acquisition rights exercised was 28,300 cases, representing 5.9% of the total issued amount of 480,000 cases. The number of unexercised stock acquisition rights at month-end was 408,700 shares, compared with 437,000 shares at the end of the previous month. For the 71st rights, disclosure of monthly exercise status is omitted because they are awaiting start-of-exercise instructions.

Exercise Restrictions and Future Impact

Exercise restrictions have been applied based on listing rules. The number of shares to be delivered this time is 2,830,000 shares, the listed shares are 80,247,210 shares, and the exercise ratio subject to restriction is reported as 3.5%. Under the terms of the purchase agreement, exercise in excess of restrictions is exempted when the exercise price is equal to or greater than the closing price on the date of the resolution to issue. Future treatment of the stock acquisition rights and market impact will depend on the contractual terms with EVO FUND.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

SymBio Pharmaceuticals Limited

Company overview · Stock price · Financial data · All IR

View company page →